{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:09:17Z","timestamp":1790050157984,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Riluzole is a neuroprotective drug used in the treatment of motor neurone disease. Recent evidence suggests that riluzole can up-regulate the expression and activity of the astrocyte glutamate transporter, GLT-1. Given that regulation of glutamate transport is predicted to be neuroprotective in Parkinson's disease, we tested the effect of riluzole in parkinsonian rats which had received a unilateral 6-hydroxydopamine injection into the median forebrain bundle.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Rats were treated with intraperitoneal riluzole (4 mg\/kg or 8 mg\/kg), 1 hour before the lesion then once daily for seven days. Riluzole produced a modest but significant attenuation of dopamine neurone degeneration, assessed by suppression of amphetamine-induced rotations, preservation of tyrosine hydroxylase positive neuronal cell bodies in the substantia nigra pars compacta and attenuation of striatal tyrosine hydroxylase protein loss. Seven days after 6-hydroxydopamine lesion, reactive astrocytosis was observed in the striatum, as determined by increases in expression of glial fibrillary acidic protein, however the glutamate transporter, GLT-1, which is also expressed in astrocytes was not regulated by the lesion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results confirm that riluzole is a neuroprotective agent in a rodent model of parkinson's disease. Riluzole administration did not regulate GLT-1 levels but significantly reduced GFAP levels, in the lesioned striatum. Riluzole suppression of reactive astrocytosis is an intriguing finding which might contribute to the neuroprotective effects of this drug.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2202-13-38","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T10:14:30Z","timestamp":1333620870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Riluzole neuroprotection in a parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation"],"prefix":"10.1186","volume":"13","author":[{"given":"Marica","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Rattray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"2502_CR1","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.expneurol.2009.09.027","volume":"220","author":"WM Caudle","year":"2009","unstructured":"Caudle WM, Zhang J: Glutamate, excitotoxicity, and programmed cell death in parkinson disease. Exp Neurol. 2009, 220: 230-233. 10.1016\/j.expneurol.2009.09.027.","journal-title":"Exp Neurol"},{"key":"2502_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1476-5381.2010.00882.x","volume":"161","author":"S Duty","year":"2010","unstructured":"Duty S: Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol. 2010, 161: 271-287. 10.1111\/j.1476-5381.2010.00882.x.","journal-title":"Br J Pharmacol"},{"key":"2502_CR3","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1212\/WNL.66.10_suppl_4.S24","volume":"66","author":"P Jenner","year":"2006","unstructured":"Jenner P, Olanow CW: The pathogenesis of cell death in Parkinson's disease. Neurology. 2006, 66: S24-36.","journal-title":"Neurology"},{"key":"2502_CR4","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/j.1476-5381.2010.00820.x","volume":"160","author":"P Austin","year":"2010","unstructured":"Austin P, Betts M, Broadstock M, O'Neill M, Mitchell S, Duty S: Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol. 2010, 160: 1741-1753. 10.1111\/j.1476-5381.2010.00820.x.","journal-title":"Br J Pharmacol"},{"key":"2502_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1471-4159.2007.04860.x","volume":"103","author":"AC Vernon","year":"2007","unstructured":"Vernon AC, Zbarsky V, Datla KP, Croucher MJ, Dexter DT: Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Neurochem. 2007, 103: 1075-1091. 10.1111\/j.1471-4159.2007.04860.x.","journal-title":"J Neurochem"},{"key":"2502_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/ana.410300513","volume":"30","author":"T Klockgether","year":"1991","unstructured":"Klockgether T, Turski L, Honore T, Zhang ZM, Gash DM, Kurlan R, Greenamyre JT: The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol. 1991, 30: 717-723. 10.1002\/ana.410300513.","journal-title":"Ann Neurol"},{"key":"2502_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1046\/j.1471-4159.1999.0730344.x","volume":"73","author":"M Vila","year":"1999","unstructured":"Vila M, Marin C, Ruberg M, Jimenez A, Raisman-Vozari R, Agid Y, Tolosa E, Hirsch EC: Systemic Administration of NMDA and AMPA Receptor Antagonists Reverses the Neurochemical Changes Induced by Nigrostriatal Denervation in Basal Ganglia. J Neurochem. 1999, 73: 344-352.","journal-title":"J Neurochem"},{"key":"2502_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.bjp.0706949","volume":"150","author":"PM Beart","year":"2007","unstructured":"Beart PM, O'Shea RD: Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007, 150: 5-17.","journal-title":"Br J Pharmacol"},{"key":"2502_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00441-004-0944-0","volume":"318","author":"P Teismann","year":"2004","unstructured":"Teismann P, Schulz JB: Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res. 2004, 318: 149-161. 10.1007\/s00441-004-0944-0.","journal-title":"Cell Tissue Res"},{"key":"2502_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.expneurol.2004.07.004","volume":"190","author":"AG Dervan","year":"2004","unstructured":"Dervan AG, Meshul CK, Beales M, McBean GJ, Moore C, Totterdell S, Snyder AK, Meredith GE: Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp Neurol. 2004, 190: 145-156. 10.1016\/j.expneurol.2004.07.004.","journal-title":"Exp Neurol"},{"key":"2502_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0361-9230(86)90119-X","volume":"17","author":"I Stromberg","year":"1986","unstructured":"Stromberg I, Bjorklund H, Dahl D, Jonsson G, Sundstrom E, Olson L: Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull. 1986, 17: 225-236. 10.1016\/0361-9230(86)90119-X.","journal-title":"Brain Res Bull"},{"key":"2502_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neuroscience.2010.12.005","volume":"175","author":"S Walsh","year":"2011","unstructured":"Walsh S, Finn DP, Dowd E: Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience. 2011, 175: 251-261.","journal-title":"Neuroscience"},{"key":"2502_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.nurt.2010.07.003","volume":"7","author":"ME Hamby","year":"2010","unstructured":"Hamby ME, Sofroniew MV: Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics. 2010, 7: 494-506. 10.1016\/j.nurt.2010.07.003.","journal-title":"Neurotherapeutics"},{"key":"2502_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuint.2011.10.017","volume":"60","author":"M Carbone","year":"2012","unstructured":"Carbone M, Duty S, Rattray M: Riluzole elevates GLT-1 activity and levels in striatal astrocytes. Neurochem Int. 2012, 60: 31-38. 10.1016\/j.neuint.2011.10.017.","journal-title":"Neurochem Int"},{"key":"2502_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/mds.20976","volume":"21","author":"W Bara-Jimenez","year":"2006","unstructured":"Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN: Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord. 2006, 21: 1380-1383. 10.1002\/mds.20976.","journal-title":"Mov Disord"},{"key":"2502_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00002826-200401000-00008","volume":"27","author":"CA Braz","year":"2004","unstructured":"Braz CA, Borges V, Ferraz HB: Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol. 2004, 27: 25-29. 10.1097\/00002826-200401000-00008.","journal-title":"Clin Neuropharmacol"},{"key":"2502_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1353-8020(01)00040-2","volume":"8","author":"J Jankovic","year":"2002","unstructured":"Jankovic J, Hunter C: A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002, 8: 271-276. 10.1016\/S1353-8020(01)00040-2.","journal-title":"Parkinsonism Relat Disord"},{"key":"2502_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0306-4522(96)00249-7","volume":"74","author":"P Barneoud","year":"1996","unstructured":"Barneoud P, Mazadier M, Miquet JM, Parmentier S, Dubedat P, Doble A, Boireau A: Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience. 1996, 74: 971-983.","journal-title":"Neuroscience"},{"key":"2502_CR19","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1097\/00001756-199412000-00063","volume":"5","author":"A Boireau","year":"1994","unstructured":"Boireau A, Dubedat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A: Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport. 1994, 5: 2657-2660. 10.1097\/00001756-199412000-00063.","journal-title":"Neuroreport"},{"key":"2502_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0304-3940(01)02176-0","volume":"312","author":"T Araki","year":"2001","unstructured":"Araki T, Muramatsu Y, Tanaka K, Matsubara M, Imai Y: Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice. Neurosci Lett. 2001, 312: 50-54. 10.1016\/S0304-3940(01)02176-0.","journal-title":"Neurosci Lett"},{"key":"2502_CR21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0028-3908(99)00188-4","volume":"39","author":"A Boireau","year":"2000","unstructured":"Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S: The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology. 2000, 39: 1016-1020. 10.1016\/S0028-3908(99)00188-4.","journal-title":"Neuropharmacology"},{"key":"2502_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0014-2999(95)00362-O","volume":"284","author":"A Benazzouz","year":"1995","unstructured":"Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C: Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol. 1995, 284: 299-307. 10.1016\/0014-2999(95)00362-O.","journal-title":"Eur J Pharmacol"},{"key":"2502_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0014-2999(98)00537-8","volume":"356","author":"E Bezard","year":"1998","unstructured":"Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE: Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. Eur J Pharmacol. 1998, 356: 101-104. 10.1016\/S0014-2999(98)00537-8.","journal-title":"Eur J Pharmacol"},{"key":"2502_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/mds.1272","volume":"17","author":"MC Obinu","year":"2002","unstructured":"Obinu MC, Reibaud M, Blanchard V, Moussaoui S, Imperato A: Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov Disord. 2002, 17: 13-19. 10.1002\/mds.1272.","journal-title":"Mov Disord"},{"key":"2502_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.neuropharm.2011.11.016","volume":"62","author":"PS Verhave","year":"2012","unstructured":"Verhave PS, Jongsma MJ, Van Den Berg RM, Vanwersch RA, Smit AB, Philippens IH: Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model. Neuropharmacology. 2012, 62: 1700-1707. 10.1016\/j.neuropharm.2011.11.016.","journal-title":"Neuropharmacology"},{"key":"2502_CR26","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.neuropharm.2006.04.015","volume":"51","author":"NP Visanji","year":"2006","unstructured":"Visanji NP, O'Neill MJ, Duty S: Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology. 2006, 51: 506-516. 10.1016\/j.neuropharm.2006.04.015.","journal-title":"Neuropharmacology"},{"key":"2502_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P: Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011, 164: 1357-1391. 10.1111\/j.1476-5381.2011.01426.x.","journal-title":"Br J Pharmacol"},{"key":"2502_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0091-3057(80)90353-6","volume":"12","author":"F Hefti","year":"1980","unstructured":"Hefti F, Melamed E, Sahakian BJ, Wurtman RJ: Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav. 1980, 12: 185-188. 10.1016\/0091-3057(80)90353-6.","journal-title":"Pharmacol Biochem Behav"},{"key":"2502_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/exnr.1998.6848","volume":"152","author":"D Kirik","year":"1998","unstructured":"Kirik D, Rosenblad C, Bjorklund A: Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol. 1998, 152: 259-277. 10.1006\/exnr.1998.6848.","journal-title":"Exp Neurol"},{"key":"2502_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/0306-4522(95)00571-4","volume":"72","author":"CS Lee","year":"1996","unstructured":"Lee CS, Sauer H, Bjorklund A: Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat. Neuroscience. 1996, 72: 641-653. 10.1016\/0306-4522(95)00571-4.","journal-title":"Neuroscience"},{"key":"2502_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1046\/j.1460-9568.2000.00896.x","volume":"12","author":"P Barneoud","year":"2000","unstructured":"Barneoud P, Descombris E, Aubin N, Abrous DN: Evaluation of simple and complex sensorimotor behaviours in rats with a partial lesion of the dopaminergic nigrostriatal system. Eur J Neurosci. 2000, 12: 322-336. 10.1046\/j.1460-9568.2000.00896.x.","journal-title":"Eur J Neurosci"},{"key":"2502_CR32","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1523\/JNEUROSCI.09-11-03720.1989","volume":"9","author":"C Malgouris","year":"1989","unstructured":"Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A, Blanchard JC, Laduron PM: Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci. 1989, 9: 3720-3727.","journal-title":"J Neurosci"},{"key":"2502_CR33","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet. 1996, 347: 1425-1431.","journal-title":"Lancet"},{"key":"2502_CR34","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","volume":"61","author":"Group HS","year":"2003","unstructured":"Group HS: Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003, 61: 1551-1556.","journal-title":"Neurology"},{"key":"2502_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","volume":"17","author":"MC Bellingham","year":"2011","unstructured":"Bellingham MC: A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci Ther. 2011, 17: 4-31. 10.1111\/j.1755-5949.2009.00116.x.","journal-title":"CNS Neurosci Ther"},{"key":"2502_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0014-2999(95)00380-4","volume":"284","author":"PA Loschmann","year":"1995","unstructured":"Loschmann PA, Eblen F, Wullner U, Wachtel H, Kockgether T: Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease. Eur J Pharmacol. 1995, 284: 129-134. 10.1016\/0014-2999(95)00380-4.","journal-title":"Eur J Pharmacol"},{"key":"2502_CR37","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1111\/j.1460-9568.2008.06211.x","volume":"27","author":"N Lamanauskas","year":"2008","unstructured":"Lamanauskas N, Nistri A: Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008, 27: 2501-2514. 10.1111\/j.1460-9568.2008.06211.x.","journal-title":"Eur J Neurosci"},{"key":"2502_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1471-4159.2001.00572.x","volume":"79","author":"C Bendotti","year":"2001","unstructured":"Bendotti C, Tortarolo M, Suchak SK, Calvaresi N, Carvelli L, Bastone A, Rizzi M, Rattray M, Mennini T: Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem. 2001, 79: 737-746.","journal-title":"J Neurochem"},{"key":"2502_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.neuron.2009.02.010","volume":"61","author":"Y Yang","year":"2009","unstructured":"Yang Y, Gozen O, Watkins A, Lorenzini I, Lepore A, Gao Y, Vidensky S, Brennan J, Poulsen D, Won Park J, et al: Presynaptic Regulation of Astroglial Excitatory Neurotransmitter Transporter GLT1. Neuron. 2009, 61: 880-894. 10.1016\/j.neuron.2009.02.010.","journal-title":"Neuron"},{"key":"2502_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1046\/j.1471-4159.2001.00644.x","volume":"79","author":"JC Lievens","year":"2001","unstructured":"Lievens JC, Salin P, Nieoullon A, Kerkerian-Le Goff L: Nigrostriatal denervation does not affect glutamate transporter mRNA expression but subsequent levodopa treatment selectively increases GLT1 mRNA and protein expression in the rat striatum. J Neurochem. 2001, 79: 893-902.","journal-title":"J Neurochem"},{"key":"2502_CR41","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/syn.20163","volume":"57","author":"HK Holmer","year":"2005","unstructured":"Holmer HK, Keyghobadi M, Moore C, Menashe RA, Meshul CK: Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration. Synapse. 2005, 57: 100-112. 10.1002\/syn.20163.","journal-title":"Synapse"},{"key":"2502_CR42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.neuint.2010.07.004","volume":"57","author":"A Massie","year":"2010","unstructured":"Massie A, Goursaud S, Schallier A, Vermoesen K, Meshul CK, Hermans E, Michotte Y: Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats. Neurochem Int. 2010, 57: 572-578. 10.1016\/j.neuint.2010.07.004.","journal-title":"Neurochem Int"},{"key":"2502_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cne.21852","volume":"511","author":"E Chung","year":"2008","unstructured":"Chung E, Chen L, Chan Y, Yung K: Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats. J Comp Neurol. 2008, 511: 421-437. 10.1002\/cne.21852.","journal-title":"J Comp Neurol"},{"key":"2502_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.brainres.2005.04.073","volume":"1049","author":"YL Yang","year":"2005","unstructured":"Yang YL, Meng CH, Ding JH, He HR, Ellsworth K, Wu J, Hu G: Iptakalim hydrochloride protects cells against neurotoxin-induced glutamate transporter dysfunction in in vitro and in vivo models. Brain Res. 2005, 1049: 80-88. 10.1016\/j.brainres.2005.04.073.","journal-title":"Brain Res"},{"key":"2502_CR45","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.tins.2009.08.002","volume":"32","author":"MV Sofroniew","year":"2009","unstructured":"Sofroniew MV: Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32: 638-647. 10.1016\/j.tins.2009.08.002.","journal-title":"Trends Neurosci"},{"key":"2502_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00702-004-0206-z","volume":"112","author":"E Diguet","year":"2005","unstructured":"Diguet E, Fernagut PO, Scherfler C, Wenning G, Tison F: Effects of riluzole on combined MPTP+ 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J Neural Transm. 2005, 112: 613-631. 10.1007\/s00702-004-0206-z.","journal-title":"J Neural Transm"},{"key":"2502_CR47","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1471-4159.2010.06896.x","volume":"114","author":"J Iczkiewicz","year":"2010","unstructured":"Iczkiewicz J, Broom L, Cooper JD, Wong AM, Rose S, Jenner P: The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem. 2010, 114: 1792-1804. 10.1111\/j.1471-4159.2010.06896.x.","journal-title":"J Neurochem"},{"key":"2502_CR48","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.neuroscience.2005.05.016","volume":"134","author":"DJ De Silva","year":"2005","unstructured":"De Silva DJ, French SJ, Cheung NY, Swinson AK, Bendotti C, Rattray M: Rat brain serotonin neurones that express neuronal nitric oxide synthase have increased sensitivity to the substituted amphetamine serotonin toxins 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Neuroscience. 2005, 134: 1363-1375. 10.1016\/j.neuroscience.2005.05.016.","journal-title":"Neuroscience"},{"key":"2502_CR49","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1471-4159.2003.01553.x","volume":"84","author":"SK Suchak","year":"2003","unstructured":"Suchak SK, Baloyianni NV, Perkinton MS, Williams RJ, Meldrum BS, Rattray M: The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J Neurochem. 2003, 84: 522-532. 10.1046\/j.1471-4159.2003.01553.x.","journal-title":"J Neurochem"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2202-13-38.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:52:06Z","timestamp":1630522326000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/1471-2202-13-38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["2502"],"URL":"https:\/\/doi.org\/10.1186\/1471-2202-13-38","relation":{},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]},"assertion":[{"value":"19 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"38"}}